PDCD1 and lung carcinoma: In lung cancer, anti-PD-1 and anti-PD-L1 monoclonal antibodies have demonstrated considerable activity, showing remarkable results in survival, long-term responses, and good immune profile compared to cytotoxic chemotherapy (71).